Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
15 results
  • Cellular Therapy, Ovarian Cancer

22-540          Phase II

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube (View details on clinicaltrial.gov)

  • Cellular Therapy

22-192          Phase II

A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia (View details on clinicaltrial.gov)

  • Cellular Therapy, Lymphoma

22-383          Phase II

A Phase 1/2, Open-Label, First-in-Human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects with CD5+ Relapsed/ Refractory Peripheral T Cell Lymphoma (View details on clinicaltrial.gov)

  • Cellular Therapy, Sarcoma

19-477          Phase II

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (View details on clinicaltrial.gov)

  • Lymphoma, Cellular Therapy

21-422          Phase II

A Phase 2 Study of acalabrutinib in combination with lisocabtagene maraleucel in relapsed/refractory aggressive B-cell lymphomas (View details on clinicaltrial.gov)

  • Multiple Myeloma, Cellular Therapy

18-604          Phase II

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2). (View details on clinicaltrial.gov)

  • Cellular Therapy, Lymphoma

20-011          Phase II

A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) (View details on clinicaltrial.gov)

  • Cellular Therapy, Lymphoma, Leukemia

19-087          Phase I

A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies (View details on clinicaltrial.gov)

  • Cellular Therapy, Multiple Myeloma

20-518          Phase I

A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Cellular Therapy, Lymphoma

22-258          Phase II

A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (View details on clinicaltrial.gov)

Showing 1 - 10 of 15 results